09:07 AM EDT, 08/20/2025 (MT Newswires) -- Mural Oncology ( MURA ) shares were up 15% premarket Wednesday after the company said it has agreed to be acquired by XOMA Royalty ( XOMA ) through its newly-formed subsidiary XRA 5 in an all-cash deal.

Under the agreement, Mural shareholders will receive a base price of $2.035 per share with the potential for up to an additional $0.205 per share depending on Mural's net cash position at closing.

The deal values Mural at about $36.2 million excluding any additional consideration, Mural said.

The transaction represents a 13.1% premium to Mural's Aug. 19 closing price and a 97.6% premium to its April 14 closing price, which was the last day before Mural announced the start of a strategic review, the company said.

Both boards have approved the acquisition which is expected to close by the end of 2025, Mural said.